popburner wrote:Ok - this is terribly interesting!! My question is how does a steroid work to fend off an enzyme deficiency? Maybe that was answered in the past few posts but was beyond my level of understanding

-- I'm going to print this topic out and send it to my mother who's a biochemist to explain I think....:)
See my post from March 10 (reposted below FYI).
Best,
JD
Adrenocortical Hormone Abnormalities in Men with CP/CPPS
by J Dimitrakov on Mon Mar 10, 2008 10:40 pm
Webslave,
You raise the most important question regarding the implications of the study: the cause and effect relationship. Our study was not designed to look at this question, since, for a start, we basically looked at the three pathways involved and tried to discern a pattern. Our approach was totally agnostic of the disease mechanisms or pathways.
It’s difficult to explain the study before a picture but if you find a scheme of the pathways online, it would be easy to understand. Basically, cholesterol from diet is used in the adrenal gland to produce aldosterone, cortisol and sex steroids (testosterone and dehydrotestosterone). These are three separate pathways that are related by virtue of common enzymes (e.g., CYP21A2).
Now on to your question. The way the body works is that CORTISOL levels feed onto the hypothalamus and the pituitary. When cortisol is low (as has been documented in several IC and CPPS studies), the low cortisol signals to the hypothalamus and the pituitary. The hypothalamus releases CRH (corticotrophin releasing hormone) which causes the release of ACTH from the pituitary. That ACTH signal drives the adrenal crazy (in an attempt to make more cortisol) which is impossible due to a block at the level of CYP21A2. Therefore, all substances before the block increase and those after the block decrease.
Is it inborn or acquired? As we state in the article, "CYP21A2 defects traditionally have been described in patients with congenital adrenal hyperplasia (CAH). The hormonal defects in our CP/CPPS population suggest that some might have an inherited or acquired form of nonclassic CAH due to CYP21A2 deficiency. Classic CAH presents with salt wasting or genital ambiguity in infants. In contrast, nonclassic (also known as mild or late-onset) CAH is characterized by partial CYP21A2 deficiency and varying signs of hyperandrogenism—abnormalities that are generally thought to be asymptomatic in men. (Ref 15, 16) In our study, the patients with CP/CPPS also had hormonal evidence of hyperandrogenism, elevated androstenedione and elevated testosterone levels, compared with the controls, a finding that further supports the presence of reduced CYP21A2 activity."
As it turns out, Dr. New in NYC has published on a series of men with nonclassic CYP21A2 (New MI: Extensive clinical experience: nonclassical 21-hydroxylase deficiency. J Clin Endocrinol Metab 91: 4205–4214, 2006, reference #16 in our paper) The symptoms of this non-classic CYP21A2 are quite non-specific and have not been studied in men with CPPS.
Anyway, the bottom-line is that men with CPPS, based on our findings, have either a variable degree of inborn or acquired CYP21A2 deficit. This finding deserves to be studied further in larger patient populations. Good news is that the ones that are found to have the CYP21A2 mutation can benefit from targeted treatments and the test we describe can be used to guide such treatments.
Best,
JD